Article: Nicotinamide Riboside Supplementation Reduces Inflammation in Heart Failure Patients: Clinical Findings

Cardiovascular Disease Cardiovascular Health Clinical Inflammation

Nicotinamide Riboside Supplementation Reduces Inflammation in Heart Failure Patients: Clinical Findings

Objectives

To investigate the mechanistic link between mitochondrial dysfunction and inflammatory activation in peripheral blood mononuclear cells (PBMCs), and the potential antiinflammatory effect of boosting NAD+ levels.

Journal

Journal of Clinical Investigation

Key Outcomes

NR supplementation increased whole blood NAD+ levels and mitochondrial respiration rate of the heart failure patients' PBMCs.
NR reduced the production and gene expression of proinflammatory cytokines.
The systemic inflammation in heart failure patients was causally linked to mitochondrial function of the PBMCs.

Duration

5-9 days

Dose

2000 mg

Study Design

Ex vivo and pilot clinical study in 5 Stage D heart failure patients

See Published Study

Clinical

Nicotinamide Riboside Supplementation Combined with Metabolic Cofactors Shows Promise for NAFLD: Clinical Findings

Objectives To assess the tolerability and metabolic effects of combined supplementation with combined metabolic activators (CMA), L-serine, NAC, nicotinamide riboside, and L-carnitine in healthy h...